Sanofi Pulls Back On French Layoff Plans After Government Pressure
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi says it will cut up to 900 jobs in France over the next three years to make its R&D operations there more efficient – that’s less than half the number foreshadowed in July by French trade unions and after the drug maker came under public pressure from the country’s left-wing government.
You may also be interested in...
European Notebook: Sanofi Exiting Toulouse; Job Cuts At Pierre Fabre; Generics Suspended In Four States
The newly formed European Commission sets out plans to improve industrial growth and international trade while leading French pharma companies Sanofi and Pierre Fabre announce plans to trim their R&D workforces. Asian companies in contrast are seeking growth opportunities in Europe, including India’s Cipla and Thailand’s CP Group.
European Notebook: Sanofi Exiting Toulouse; Job Cuts At Pierre Fabre; Generics Suspended In Four States
The newly formed European Commission sets out plans to improve industrial growth and international trade while leading French pharma companies Sanofi and Pierre Fabre announce plans to trim their R&D workforces. Asian companies in contrast are seeking growth opportunities in Europe, including India’s Cipla and Thailand’s CP Group.
European Notebook: Sanofi, AstraZeneca Seek New Uses For Old R&D Sites
VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.